Shanghai Fosun gets approval for RMB 2 billion MTNs, taps two leads

By Marisa Wong

Madison, Wis., April 7 – Shanghai Fosun Pharmaceutical (Group) Co., Ltd. plans to issue up to RMB 2 billion of mid-term notes. China’s National Association of Financial Market Institutional Investors approved the proposed issuance on April 3, according to a company announcement.

The joint lead underwriters are Industrial and Commercial Bank of China Ltd. and the Export-Import Bank of China.

The notes may be issued in one or more tranches within two years.

The notes were first proposed in October 2013.

The pharmaceutical company is a Shanghai-based member of the Hong Kong group Fosun International Ltd.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.